People

Keith A. Johnson, MD, is Professor of Radiology and Neurology at Harvard Medical School and Associate Radiologist and Director of Molecular Neuroimaging at Massachusetts General Hospital. He is co-director of the Neuroimaging Program of the Massachusetts Alzheimer's Disease Research Center and its DIAN research initiatives, and oversees the Clinical Brain PET Service at MGH. His major research interests include normal brain aging and the early diagnosis and treatment monitoring of neurodegenerative diseases including Alzheimer's, Parkinson's, and dementia with Lewy bodies.

As Chief Science Officer, Maria Carrillo sets the strategic vision for the Alzheimer's Association global research program. She oversees the AAIC, the world's largest dementia science meeting, and manages the World Wide ADNI initiative. Dr. Carrillo earned her doctorate from Northwestern University and completed a postdoctoral fellowship at Rush University Medical Center.

Dr. Mormino completed her PhD in Neuroscience at UC Berkeley in the laboratory of Dr. William Jagust, where she performed some of the initial studies applying Amyloid PET to clinically normal older individuals. During her postdoctoral fellowship at MGH she used multimodal imaging to understand longitudinal cognitive changes in preclinical AD. Her research program at Stanford, where she currently serves as Associate Professor, focuses on combining imaging and genetics to predict cognitive trajectories over time.

Julie Price, PhD, is Investigator and Professor in the Department of Radiology at MGH and Director of PET Pharmacokinetic Modeling at the Athinoula A. Martinos Center. Her expertise is in PET imaging methodology for translational imaging of protein targets in aging and neurodegeneration. She is a 2021 Fellow of SNMMI and 2021 SNMMI Brain Imaging Council Kuhl-Lassen awardee.

Keith A. Johnson, MD, is Professor of Radiology and Neurology at Harvard Medical School and Associate Radiologist and Director of Molecular Neuroimaging at Massachusetts General Hospital. He is co-director of the Neuroimaging Program of the Massachusetts Alzheimer's Disease Research Center and its DIAN research initiatives, and oversees the Clinical Brain PET Service at MGH. His major research interests include normal brain aging and the early diagnosis and treatment monitoring of neurodegenerative diseases including Alzheimer's, Parkinson's, and dementia with Lewy bodies.

As Chief Science Officer, Maria Carrillo sets the strategic vision for the Alzheimer's Association global research program. She oversees the AAIC, the world's largest dementia science meeting, and manages the World Wide ADNI initiative. Dr. Carrillo earned her doctorate from Northwestern University and completed a postdoctoral fellowship at Rush University Medical Center.

Dr. Ikonomovic's primary research interests are aging and Alzheimer's Disease, focusing on mechanisms underlying selective neuronal vulnerability in relation to neuropathology changes and cognitive impairment. His research addresses development and neuropathological validation of novel PET radioligands and blood biomarkers for in vivo detection of pathological protein changes in AD and related disorders. He has published over 150 original peer-reviewed scientific manuscripts, review articles, and book chapters.

Dr. Karikari's research aims to further understand the molecular and biochemical basis of pathological brain changes in Alzheimer's patients and to develop new biofluid-based diagnostic tools for clinical use. As a postdoctoral scholar, he developed the most widely used and reliable blood test for Alzheimer's disease to date, reliably quantifying blood p-tau across all age groups to enable diagnosis and prognosis. He serves as Director of the Mass Spectrometry Biomarker Laboratory at Pitt.

Dr. Mormino completed her PhD in Neuroscience at UC Berkeley in the laboratory of Dr. William Jagust, where she performed some of the initial studies applying Amyloid PET to clinically normal older individuals. During her postdoctoral fellowship at MGH she used multimodal imaging to understand longitudinal cognitive changes in preclinical AD. Her research program at Stanford focuses on combining imaging and genetics to predict cognitive trajectories over time.

Julie Price, PhD, is Investigator and Professor in the Department of Radiology at MGH and Director of PET Pharmacokinetic Modeling at the Athinoula A. Martinos Center. Her expertise is in PET imaging methodology for translational imaging of protein targets in aging and neurodegeneration. She is a 2021 Fellow of SNMMI and 2021 SNMMI Brain Imaging Council Kuhl-Lassen awardee.

See bio above.

See bio above.

Dr. Gomez-Isla received her medical training at the University Complutense, Madrid, and completed her neurology residency at the Hospital Doce de Octubre, Madrid. She then completed a clinical and research fellowship in the Memory Disorders and Alzheimer's Research Laboratory at MGH. She sees patients and conducts clinical research at MGH and performs basic research at the MassGeneral Institute for Neurodegenerative Disease.

See bio above.

See bio above.

See bio above.

See bio above.

William J. Jagust, MD, is Professor of Public Health and Neuroscience at UC Berkeley. Research in his lab is aimed at understanding the structural, functional, and biochemical basis of brain aging and neurodegenerative diseases. Dr. Jagust uses PET, MRI, fMRI, and neuropsychology to study normal older people and patients with Alzheimer's disease and related dementias and Parkinson's disease.

William E. Klunk, MD, PhD, is co-director of the Alzheimer Disease Research Center at UPMC and professor of psychiatry and neurology at the University of Pittsburgh. Dr. Klunk is a pioneer in the field of in vivo amyloid imaging in humans and a member of the Pitt team that invented Pittsburgh Compound B (PiB). His group's 2004 paper on imaging the pathology of Alzheimer's disease is the most frequently cited research paper on this disease.

Chester Mathis, PhD, has a long-standing interest in applying synthetic radiochemistry to develop PET radiopharmaceuticals to study brain function in vivo. As Director of the University of Pittsburgh PET Facility, Dr. Mathis works closely with over 25 investigators from 8 departments on more than 70 PET research imaging protocols. He joined efforts with Dr. William E. Klunk to develop Pittsburgh Compound-B for non-invasive assessment of amyloid load in the living human brain.

See bio above.